A GLP-1 receptor PET imaging add-on study within the VERA-T1D trial investigating the effects on beta cell mass (Image-VER-A-T1D)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518554-17-00

Enrollment

Registered

2025-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes mellitus

Brief summary

The total pancreatic uptake of 68Ga-NODAGA-exendin for determination of beta cell mass at the point of inclusion and after 12 months.

Detailed description

Changes in 68Ga-NODAGA-exendin pancreas uptake in realtion to changes in C-peptide measurements., Changes in 68Ga-NODAGA-exendin pancreas uptake in relation to changes in proinsulin/preproinsulin measurements., Differences in 68Ga-NODAGA-exendin uptake between individuals and between the two timepoints of imaging intra-individually

Interventions

DRUGEXENATIDE

DRUGVERAPAMIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The total pancreatic uptake of 68Ga-NODAGA-exendin for determination of beta cell mass at the point of inclusion and after 12 months.	—

Secondary

Measure	Time frame
Changes in 68Ga-NODAGA-exendin pancreas uptake in realtion to changes in C-peptide measurements., Changes in 68Ga-NODAGA-exendin pancreas uptake in relation to changes in proinsulin/preproinsulin measurements., Differences in 68Ga-NODAGA-exendin uptake between individuals and between the two timepoints of imaging intra-individually	—

Countries

Austria, France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026